Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Bio

Sandy Srinivas specializes in urologic oncology and takes care of patients with prostate, bladder, kidney, testes, penile and adrenal cancers. She has practiced in this field now for more than 20 years . She is the clinical research group leader for Urologic Program at Stanford and is a principal investigator on numerous trials in urologic Oncology and is the medical director for the in-patient hematology Oncology unit . She serves as the Vice chair on the National Comphrehensive Cancer Center (NCCN) panel for prostate cancer and has coauthored numerous publications and book chapters. She has received numerous teaching awards and is a nationally recognized expert in the field of Urologic Oncology.

Clinical Focus

Cancer > Urologic Oncology
Bladder Cancer
Bladder Cancer - Medical Oncology
Germ Cell Tumors
Germ Cell Tumors - Medical Oncology
Germ Cell Tumors - Urologic Oncology
Kidney Cancer
Kidney Cancer - Medical Oncology
Male Cancers - Penile
Male Cancers - Prostate
Male Cancers - Testicular
Oncology (Cancer)
Penile Cancer
Prostate Cancer
Prostate Cancer - Medical Oncology
Testicular Tumors
Testicular Tumors - Medical Oncology
Ureteral Cancer
Ureteral Cancer - Medical Oncology
Urethral Cancer
Urethral Cancer - Medical Oncology
Urologic Cancers
Urologic Cancers - Medical Oncology
Medical Oncology

Academic Appointments

Professor - University Medical Line, Medicine - Oncology
Professor - University Medical Line (By courtesy), Urology
Member, Stanford Cancer Institute

Administrative Appointments

DSMC Vice Chair, Stanford University (2002 - 2019)
Prostate Panel member, NCCN (2002 - Present)
Unit based Medical Director, Stanford Hospital (2012 - Present)

Honors & Awards

Oncology Teaching award, Stanford University (2002)
Medicine Chief residents teaching award, Stanford University (2003)
Oncology clinical fellows teaching award, Stanford University (2003)
Oncology Clinical Fellows teaching award, Stanford University (2004)
Oncology Clinical Fellows Teaching award, Stanford University (2005)
Oncology Clinical Fellows Teaching award, Stanford University (2006)
Oncology Clinical Fellows teaching award, Stanford University (2007)
Oncology Clinical Fellows Teaching award, Stanford University (2008)
Oncology Clinical Fellows Teaching award, Stanford University (2009)
Oncology Clinical Fellows teaching award, Stanford University (2012)
Oncology Clinical Fellows Teaching award, Stanford University (2013)
Saul Rosenberg clinical fellows teaching award, Stanford University (2015)
Saul Rosenberg clinical Fellows teaching award, Stanford University (2016)
Denise O'Leary Clinical Excellence Award, Stanford Hospital Board of Directors (2018)

Professional Education

Board Certification: American Board of Internal Medicine, Medical Oncology (2009)
Fellowship: UCSF Hematology and Medical Oncology Fellowship (1994) CA
Residency: Rochester Regional Health at Unity Hospital Internal Medicine Residency (1991) NY
Medical Education: Madras University Medicine (1985) India

Contact

Academic sandysri@stanford.edu Tel: (650) 725-2078 Fax: (650) 736-1640

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Uro-Oncology Clinic 875 Blake Wilbur Dr Clinic E MC 6513 Stanford CA 94305 Tel: (650) 498-6000 Fax: (650) 736-1640

Additional Clinical Info

Stanford Health Care

Current Research and Scholarly Interests

The Genito-Urinary Multidisciplinary tumor board at Stanford specalizes in taking care of patients with prostate cancer, renal cancer, testicular and bladder cancer. Patients are seen at different stages of their tumor. A multisdiscplinary approach is used. A variety of clinical trials are available to patients. Phase II trials using unique combination of chemotherapy agents, antiangiogenic drugs, novel agents are being explored.Co-operative group particpation through ECOG is also available

Clinical Trials

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols Not Recruiting
More
Open-label, multi-center, multi-national rollover study to allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy or combination) protocols. Eligible subjects will continue to receive tivozanib at the same dose and schedule as per the original (parent) protocol. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the (original) parent protocol. Subjects will be seen by the investigator every 4 weeks (± 5 days). Adverse events and blood pressure will be recorded. At the beginning of Cycle 1 and at the beginning of every odd-numbered cycle (Cycle 3, Cycle 5, etc), clinical laboratory values will be recorded. CT scans to assess disease will be performed at the end of even-numbered cycles (Cycle 2, Cycle 4, etc).

Stanford is currently not accepting patients for this trial. For more information, please contact Sarah Barbeau, 6507236286.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer Not Recruiting
More
This phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if cisplatin and gemcitabine hydrochloride work better alone or with berzosertib in treating patients with urothelial cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Sandy Srinivas, 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment Not Recruiting
More
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Not Recruiting
More
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) Not Recruiting
More
The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the following: * At least 2 lines of therapy, including at least 1 vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) * Radiographic progression of metastatic RCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to cycle 1 day 1

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer Not Recruiting
More
The purpose of this study is to evaluate the objective response rate (complete response \[CR\]+ partial response \[PR\]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma Not Recruiting
More
This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
View full details
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer Not Recruiting
More
The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel, and to see whether adding AS1404 and docetaxel together improves the outcome of the treatment, when compared to docetaxel alone.

Stanford is currently not accepting patients for this trial. For more information, please contact Ruth Lira, 6507231367.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Not Recruiting
More
This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate Not Recruiting
More
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with abiraterone and steroids. In Part A (Phase 1), patients will continue to receive the same doses of abiraterone and steroids they were receiving prior to study entry and will be randomized to receive 1 of 2 different treatment regimens of AT13387 in combination with abiraterone. Once the best regimen is established in Part A, based on safety and antitumor activity, patients will be randomized to the selected treatment regimen and dose of AT13387 in combination with abiraterone or AT13387 alone in Part B (Phase 2).

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) Not Recruiting
More
This is a Phase II, multicenter, randomized, blinded, placebo-controlled study designed to evaluate the safety and efficacy of combining bevacizumab with sunitinib relative to placebo with sunitinib in patients with metastatic RCC who have not received prior systemic therapy for metastatic disease. The study will enroll approximately 100 patients at approximately 20 centers in the United States.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer Recruiting
More
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer Not Recruiting
More
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Sandy Srinivas, Site 116, 650-725-2078.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Not Recruiting
More
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Not Recruiting
More
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer Not Recruiting
More
This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer Recruiting
More
This study is researching an investigational drug called REGN4336. Some participants may receive additional investigational drugs in combination with REGN4336. These additional drugs include REGN5678, cemiplimab and sarilumab. The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug) and effectiveness of REGN4336 alone, in combination with cemiplimab, or in combination with REGN5678. REGN4336, cemiplimab and REGN5678 are a type of treatment for cancer called immunotherapy,and are intended to activate T-cells to attack cancer cells. This study has 2 parts. The purpose of Part 1 is to determine a safe dose of REGN4336 when given alone or when given in combination with cemiplimab or REGN5678. The purpose of Part 2 is to use the REGN4336 dose(s) determined in Part 1 to further test how well REGN4336 works to shrink tumors either when given alone or in combination with cemiplimab or REGN5678. This study is looking at several other research questions, including: * What side effects may happen from taking REGN4336 alone, in combination with cemiplimab, or in combination with REGN5678? * How much REGN4336 is in the blood at different times when it is given alone, in combination with cemiplimab, or in combination with REGN5678? * Does the body make antibodies against the study drugs (REGN4336, cemiplimab, or REGN5678)?
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Not Recruiting
More
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer Recruiting
More
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) Not Recruiting
More
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) Not Recruiting
More
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy \[gemcitabine plus cisplatin\] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B).

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
177Lu-PSMA-617 Managed Access Program for mCRPC Patients Not Recruiting
More
The purpose of this Cohort Treatment Plan is to allow access to 177Lu-PSMA-617 for eligible patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). The patient's treating physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) Not Recruiting
More
To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment

Stanford is currently not accepting patients for this trial. For more information, please contact Christian Hoerner, PhD, 650-721-3206.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Not Recruiting
More
This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain part of the body (localized). Nivolumab is a drug that may help stimulate the immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab to the usual surgery could prevent the cancer from returning. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Site Public Contact, 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC Not Recruiting
More
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC Not Recruiting
More
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) Not Recruiting
More
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).

Stanford is currently not accepting patients for this trial. For more information, please contact Paige Baker , 650-736-3687.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer Not Recruiting
More
This phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into the deep muscle of the bladder wall (muscle-invasive) or urothelial cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Monoclonal antibodies recognizing and blocking checkpoint molecules can enhance the patient's immune response and therefore help fight cancer. Pembrolizumab is one of the monoclonal antibodies that block the PD-1 axis and can interfere with the ability of tumor cells to grow.

Stanford is currently not accepting patients for this trial. For more information, please contact Site Public Contact, 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer Not Recruiting
More
This phase II trial studies the side effects of durvalumab and chemotherapy before surgery in treating patients with variant histology bladder cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab in addition to standard chemotherapy may lead to better outcomes in patients with variant histology bladder cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Sandy Srinivas, 650-725-2078.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer Not Recruiting
More
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.

Stanford is currently not accepting patients for this trial. For more information, please contact Shermeen Poushnejad, 650-724-7662.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Not Recruiting
More
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Recruiting
More
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with \[18F\]FP-R01-MG-F2 with PET/CT

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Not Recruiting
More
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth or tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving sunitinib malate and gemcitabine hydrochloride together is more effective than sunitinib malate alone in treating patients with kidney cancer. PURPOSE: This randomized phase II clinical trial is studying giving sunitinib malate together with or without gemcitabine hydrochloride to see how well they work in treating patients with advanced kidney cancer that cannot be removed by surgery.

Stanford is currently not accepting patients for this trial. For more information, please contact Preeti Chavan, 650-723-5957.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Not Recruiting
More
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Not Recruiting
More
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
View full details
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer Not Recruiting
More
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer Not Recruiting
More
The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) Not Recruiting
More
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer Not Recruiting
More
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection Not Recruiting
More
This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants were randomized by a 1:1 ratio into atezolizumab group or control group.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma Not Recruiting
More
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Not Recruiting
More
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy Not Recruiting
More
The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive disease without clinical or radiographic evidence of metastatic disease. Cohort 2 - participants with androgen-independent metastatic prostate cancer (documented bone or soft tissue metastases) with rising PSA, clinical, radiographic disease progression following one prior docetaxel-based regimen

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Not Recruiting
More
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy but not yet received chemotherapy.

Stanford is currently not accepting patients for this trial. For more information, please contact Sarah Barbeau, 6507236286.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma Not Recruiting
More
This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer. This treatment protocol is not a clinical trial in which sorafenib is compared to another equal treatment. All patients in this protocol will be treated with sorafenib. In addition, data from the patients who participate in this protocol will provide additional information about the drug.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Not Recruiting
More
The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer Not Recruiting
More
The primary objectives of this study are the following: Phase 1b: To identify a safe dose level of AMG 102, up to 15 mg/kg Q3W, to combine with mitoxantrone and prednisone (MP) Phase 2: To estimate with adequate precision the effect of the addition of AMG 102 to MP, compared with placebo plus MP, as assessed by the hazard ratio (HR) for overall survival (OS) of previously treated subjects with castrate-resistant prostate cancer (CRPC)

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer Not Recruiting
More
This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which treatment is better.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance Not Recruiting
More
After the diagnosis of prostate cancer, many men alter their lifestyle or diet or use various supplements in an attempt to retard the growth of their cancer. While there is limited data on the use of diet and supplements to alter the risk of prostate cancer, even less is known regarding the ability of diet or supplements to alter progression. For men who have elected active surveillance, the investigators propose to investigate the ability of vitamin D to retard the growth of prostate cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office CCTO, 6504987061.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer Not Recruiting
More
This pilot phase I trial studies the side effects and best way to give stereotactic body radiation therapy and T-cell infusion in treating patients with metastatic kidney cancer. Giving total body irradiation before a T-cell infusion stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. Chemotherapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the radiation therapy.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Not Recruiting
More
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) Not Recruiting
More
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma (RCC) with clear cell component. The primary study hypothesis is that pembrolizumab is superior to placebo with respect to Disease-free Survival (DFS) as assessed by the Investigator in male and female participants with intermediate-high risk, high risk and M1 NED RCC.

Stanford is currently not accepting patients for this trial. For more information, please contact Study Coordinator, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer Not Recruiting
More
Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC). The secondary objectives were: * To assess the efficacy of aflibercept compared to placebo on other parameters such prostate-specific antigen (PSA) level, cancer related pain, progression free survival (PFS), tumor-based and skeletal events and health-related quality of life (HRQL); * To assess the overall safety in both treatment arms; * To determine the pharmacokinetics of intravenous (IV) aflibercept in this population; * to determine immunogenicity of IV aflibercept.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation Not Recruiting
More
The purpose of this study is to evaluate time to progression (TTP) by PSA in patients with high risk prostate cancer after definitive therapy.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
- Fuad Freiha
View full details
Fulvestrant in Hormone Refractory Prostate Cancer Not Recruiting
More
The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have a rising serum prostate specific antigen (PSA).

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy Not Recruiting
More
This randomized phase II clinical trial studies probiotic supplementation in preventing treatment-related diarrhea in patients with cancer undergoing chemotherapy. Probiotics may help prevent diarrhea caused by treatment with chemotherapy.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer Not Recruiting
More
Selenium, in the form of inorganic Sodium Selenite, may be useful for treating existing prostate cancer. This idea is based on data from our laboratory showing that 1) prostate cancer cells are more sensitive to Selenium (Sodium Selenite)-induced apoptosis than normal prostate epithelial cells, 2) Selenite induces significant growth inhibition of well established prostate cancer tumors in mice at doses that have no detectable toxicity, and 3) Selenite disrupts AR signaling, and that the inhibition of AR expression and activity by Selenite occurs via a redox mechanism involving GSH, superoxide, and Sp1. Altogether, these findings suggest that Selenium may be useful in a variety of potential indications in the natural history of prostate cancer, including both hormone sensitive and castrate resistant prostate cancer, as a single agent, or in combination with radiation, chemotherapy or conventional hormone therapy. Selenite is a potential novel inhibitor of AR expression and function in prostate cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
- Susan Knox
View full details
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer Not Recruiting
More
Primary: To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently. Secondary Objectives: To describe the safety and tolerability at this dose and schedule

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Not Recruiting
More
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer Not Recruiting
More
The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer. The addition of lenalidomide to docetaxel and prednisone is proposed to increase the life expectancy of these subjects.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Not Recruiting
More
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
View full details
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Not Recruiting
More
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Belle Li, .
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer Not Recruiting
More
The primary objectives of this study are: 1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC); and 2. To summarize the safety of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in this patient population.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma Not Recruiting
More
The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and Torisel™ given in combination for renal cell cancer. The study will also assess the effects of the combination of tivozanib (AV-951) and Torisel™ on the tumor. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus is an mTOR inhibitor which is approved for the treatment of advanced renal cell carcinoma.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors Not Recruiting
More
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not yet known whether high-dose combination chemotherapy and stem cell transplant are more effective than standard-dose combination chemotherapy in treating patients with refractory or relapsed germ cell tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
View full details
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) Not Recruiting
More
Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression free survival (PFS) of subjects with HRPC.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients Not Recruiting
More
This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will receive oral doses of TRC253. The study will be conducted in 2 parts: part 1 (dose escalation) and part 2 (dose expansion).

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer Not Recruiting
More
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC).

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer Not Recruiting
More
To determine: * Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate cancer. * Group A - subjects who have not previously received chemotherapy * Group B - sujects who have received prior chemotherapy or could not tolerate chemotherapy. * Clinical response will be determined by PSA and radiological response

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Not Recruiting
More
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma Not Recruiting
More
The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Not Recruiting
More
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Not Recruiting
More
This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sunitinib malate is more effective than sorafenib tosylate or placebo in treating kidney cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Harlan Pinto
- Sandy Srinivas
View full details
A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer Not Recruiting
More
The primary purpose of this study is to evaluate the ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response. Secondary goals are to describe the safety and tolerability at this dose and schedule, to determine the time to sustained biochemical response, to determine the duration of biochemical response, to determine the time to disease progression.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy Not Recruiting
More
This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI Not Recruiting
More
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

Stanford is currently not accepting patients for this trial. For more information, please contact Andrew Quon, 6507361369.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer Not Recruiting
More
This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has not responded to hormone therapy and has spread to other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors accurately measure how well patients respond to treatment with radium Ra 223 dichloride.

Stanford is currently not accepting patients for this trial. For more information, please contact Omar Rutledge, 650-721-4089.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
- Andrei Iagaru
View full details
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Not Recruiting
More
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer Not Recruiting
More
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.

Stanford is currently not accepting patients for this trial. For more information, please contact Preeti Chavan, 650-723-5957.
Lead Sponsor
Stanford Investigators
View full details
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer Not Recruiting
More
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma Not Recruiting
More
The purpose of Part 1 of this study is to evaluate the safety and tolerability of dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (RCC) to determine the recommended dose level of dalantercept in combination with axitinib for Part 2. The purpose of Part 2 of this study is to determine whether treatment with dalantercept in combination with axitinib prolongs progression free survival (PFS) compared to axitinib alone in patients with advanced renal cell carcinoma (RCC).

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) Recruiting
More
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and overall survival (OS), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer Not Recruiting
More
Determine time-to-progression (TTP) for an escalating dose schedule for subjects with progressive metastatic renal cell carcinoma treated with sorafenib

Stanford is currently not accepting patients for this trial. For more information, please contact Haas Denise, 6507361252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) Not Recruiting
More
This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts. Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. The results of Cohort 1 are reported separately (NCT02951767). Cohort 2 (reported here) will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen. Participants in both cohorts will be given a 1200 milligrams (mg) intravenous (IV) dose of atezolizumab on Day 1 of 21-day cycles. Treatment of participants in Cohort 1 will continue until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or unmanageable toxicity. Treatment of participants in Cohort 2 will continue until loss of clinical benefit or unmanageable toxicity.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets Not Recruiting
More
The primary objective is to compare the diagnostic performance of 18F- Fluoride PET/CT scanning to that of conventional bone scanning for detecting cancer that has spread to the bone (bone metastasis). The intent of the study is to determine whether 18F-Fluoride PET/CT will lead to improved treatment and patient outcomes.

Stanford is currently not accepting patients for this trial. For more information, please contact Andrei Iagaru, 6507362859.
Lead Sponsor
Stanford Investigators
- Sanjiv Sam Gambhir, MD, PhD
- Sandy Srinivas
View full details
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer Not Recruiting
More
Bone metastases and associated pain are a major cause of morbidity and mortality in castration-resistant prostate cancer (CRPC). Most approved therapies have shown some ability to reduce soft tissue lesions but none meaningfully impacts bone metastases (as demonstrated by lack of resolution of lesions on bone scan with these agents) or the pain associated with these metastases. This study will evaluate the effect of cabozantinib versus mitoxantrone plus prednisone on pain response and bone scan response in men with CRPC.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Not Recruiting
More
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bevacizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether gemcitabine hydrochloride and cisplatin are more effective when given with or without bevacizumab in treating patients with urinary tract cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Preeti Chavan, 6507250426.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma Not Recruiting
More
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Stanford is currently not accepting patients for this trial. For more information, please contact Yoriko Imae, 650-498-5186.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Not Recruiting
More
The purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT). One combination of drugs, paclitaxel, ifosfamide and cisplatin (TIP), is experimental. The other combination of drugs, bleomycin, etoposide and cisplatin (BEP), is the standard of care treatment for intermediate- and poor-risk germ cell tumors. However, BEP does not cure every patient and therefore newer treatments are needed.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Not Recruiting
More
The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be treated with cisplatin. This study will help to determine whether vinflunine in combination with gemcitabine will extend the time period until further growth of the tumor more than gemcitabine alone.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Not Recruiting
More
This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Stefanie S. Jeffrey, MD
- Sandy Srinivas
View full details
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) Not Recruiting
More
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy Not Recruiting
More
This study evaluates if itraconazole causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer Not Recruiting
More
This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys\[Ahx\]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying prostate cancer that may have returned after a period of improvement (biochemical recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer receptor, which can then be imaged by the PET/CT or PET/MRI scanner.

Stanford is currently not accepting patients for this trial. For more information, please contact Pamela Gallant, 650-736-8965.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer Not Recruiting
More
The purpose of this study is to evaluate the effect of the combination of mitoxantrone and granulocyte-macrophage colony stimulating factor (GM-CSF) on progression-free survival (PFS) and overall survival (OS), in patients with hormone-refractory prostate cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Not Recruiting
More
The purpose of this study is to determine the safety and efficacy of enzalutamide vs bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have disease progression despite primary androgen deprivation therapy.

Stanford is currently not accepting patients for this trial. For more information, please contact Sarah Barbeau, 6507236286.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Not Recruiting
More
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Jennifer Vargas, 650-723-0371.
Lead Sponsor
Stanford Investigators
View full details
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) Not Recruiting
More
This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated. An independent central pathology review of tumour samples will be used to confirm the diagnosis of PRCC of all patients enrolling. However, locally available pathology results confirming PRCC will be allowed for timely study entry.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Not Recruiting
More
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Sarah Barbeau, 6507236286.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Not Recruiting
More
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy Not Recruiting
More
RATIONALE: Studying samples of blood in the laboratory from patients receiving radiation therapy and chemotherapy may help doctors learn more about the effects of this treatment on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying biomarkers in blood samples from young patients with newly diagnosed brain tumors undergoing standard radiation therapy and chemotherapy.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) Not Recruiting
More
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

Stanford is currently not accepting patients for this trial. For more information, please contact Sarah Barbeau, 6507236286.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma Not Recruiting
More
The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer Not Recruiting
More
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Preeti Chavan, 650-725-0426.
Lead Sponsor
Stanford Investigators
- Harlan Pinto
- Sandy Srinivas
View full details
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery Not Recruiting
More
This randomized phase II trial studies how well tivantinib with or without erlotinib hydrochloride works in treating patients with metastatic or locally advanced kidney cancer that cannot be removed by surgery. Tivantinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Stanford is currently not accepting patients for this trial. For more information, please contact Preeti Chavan, 650-725-0426.
Lead Sponsor
Stanford Investigators
- Heather Wakelee
- Sandy Srinivas
View full details
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases Not Recruiting
More
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.

Stanford is currently not accepting patients for this trial. For more information, please contact Elizabeth Chitouras, 650-498-0623.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
- Andrei Iagaru
View full details
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Not Recruiting
More
The purpose of this study is to evaluate the safety and pharmacokinetics of enfortumab vedotin as well as assess the immunogenicity and antitumor activity in subjects with metastatic urothelial cancer and other malignant solid tumors that express Nectin-4.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Alice C. Fan
- Sandy Srinivas
View full details
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Not Recruiting
More
The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma Not Recruiting
More
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer Not Recruiting
More
To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sandy Srinivas
View full details
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer Not Recruiting
More
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) Not Recruiting
More
To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer

Stanford is currently not accepting patients for this trial. For more information, please contact Sarah Barbeau, 650-723-6286.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer Not Recruiting
More
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
- Sandy Srinivas
View full details

2024-25 Courses

Independent Studies
- Directed Reading in Medicine
  MED 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience in Medicine
  MED 280 (Aut, Win, Spr, Sum)
- Graduate Research
  MED 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  MED 370 (Aut, Win, Spr, Sum)
- Undergraduate Research
  MED 199 (Aut, Win, Spr, Sum)

Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators